Actual aspects of use of ergoferon in outpatient polyclinic practice

Abstract

Acute respiratory infections (ARI) and influenza are referred to the most common diseases among children and adults. Despite a wide choice of medications for this pathology, we still need ones that combine a multipurpose antiviral activity, have proven effectiveness and safety and enable application in patients from risk groups, including allergic diseases. The pharmacological activity of a release-active drug Ergoferon is determined by the complex action of its components on antiviral immune response and virus-induced inflammation in the respiratory tract. Each component at the same time has its own target modulating action, which is a distinctive property of release-active antibodies forms. The article presents an overview of Russian and foreign publications, summarizing the results of preclinical and clinical studies effectiveness and safety of the Ergoferon use for treatment and prevention of acute respiratory infections and influenza in patients of different age groups.

Keywords

• ergoferon
• release-active drug
• influenza
• acute respiratory infections (ari)